Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Altayskaya Vershina LLC owns vodka brands in the low-premium segment

12/12/24 KLVZ

Rosneft and India's Reliance conclude largest oil deal

12/12/24 ROSN

Yandex Go has launched in Turkey

12/12/24 YDEX

Samolet will update its dividend policy by mid-2025

12/12/24 SMLT

Samolet has summarized the preliminary results of 2024

12/12/24 SMLT

Shareholders of Phosagro approved dividends

12/12/24 PHOR

X5 Group opened two Chizhik distribution centers in the Urals

12/12/24 X5

Novabev Group opened the 2000th VinLab store

12/12/24 BELU

Kristall acquired a beverage distributor

12/12/24 KLVZ

Softline launched production of payment terminals

12/12/24 SOFL